Literature DB >> 20364091

KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine.

Don Ganem1.   

Abstract

The linkage of Kaposi sarcoma (KS) to infection by a novel human herpesvirus (Kaposi sarcoma-associated herpesvirus [KSHV]) is one of the great successes of contemporary biomedical research and was achieved by using advanced genomic technologies in a manner informed by a nuanced understanding of epidemiology and clinical investigation. Ongoing efforts to understand the molecular mechanisms by which KSHV infection predisposes to KS continue to be powerfully influenced by insights emanating from the clinic. Here, recent developments in KS pathogenesis are reviewed, with particular emphasis on clinical, pathologic, and molecular observations that highlight the many differences between this process and tumorigenesis by other oncogenic viruses.

Entities:  

Mesh:

Year:  2010        PMID: 20364091      PMCID: PMC2847423          DOI: 10.1172/JCI40567

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  190 in total

1.  The Kaposi's sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter.

Authors:  Hong Li; Takashi Komatsu; Bruce J Dezube; Kenneth M Kaye
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi's sarcoma-associated herpesvirus originate from a common promoter.

Authors:  Michael Pearce; Satoko Matsumura; Angus C Wilson
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex.

Authors:  N A Smith; C A Sabin; R Gopal; D Bourboulia; W Labbet; C Boshoff; D Barlow; B Band; B S Peters; A de Ruiter; D W Brown; R A Weiss; J M Best; D Whitby
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

5.  The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium.

Authors:  N S Haque; J T Fallon; M B Taubman; P C Harpel
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

7.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

Authors:  K A Staskus; W Zhong; K Gebhard; B Herndier; H Wang; R Renne; J Beneke; J Pudney; D J Anderson; D Ganem; A T Haase
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.

Authors:  G Miller; M O Rigsby; L Heston; E Grogan; R Sun; C Metroka; J A Levy; S J Gao; Y Chang; P Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

9.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.

Authors:  C Boshoff; T F Schulz; M M Kennedy; A K Graham; C Fisher; A Thomas; J O McGee; R A Weiss; J J O'Leary
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

10.  Kaposi's sarcoma in England and Wales before the AIDS epidemic.

Authors:  A E Grulich; V Beral; A J Swerdlow
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

View more
  195 in total

Review 1.  Virus-encoded microRNAs.

Authors:  Adam Grundhoff; Christopher S Sullivan
Journal:  Virology       Date:  2011-01-31       Impact factor: 3.616

2.  Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen.

Authors:  Mel Campbell; Pei-Ching Chang; Steve Huerta; Chie Izumiya; Ryan Davis; Clifford G Tepper; Kevin Y Kim; Bogdan Shevchenko; Don-Hong Wang; Jae U Jung; Paul A Luciw; Hsing-Jien Kung; Yoshihiro Izumiya
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

3.  Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV.

Authors:  Tiffany Jones; Fengchun Ye; Roble Bedolla; Yufei Huang; Jia Meng; Liwu Qian; Hongyi Pan; Fuchun Zhou; Rosalie Moody; Brent Wagner; Mazen Arar; Shou-Jiang Gao
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

4.  Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus.

Authors:  Roberto Flores; James J Goedert
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

Review 5.  Viruses and human cancer: from detection to causality.

Authors:  Ronit Sarid; Shou-Jiang Gao
Journal:  Cancer Lett       Date:  2010-10-23       Impact factor: 8.679

6.  Association of Kaposi’s sarcoma-associated herpesvirus (KSHV) with bladder cancer in Croatian patients.

Authors:  Martina Paradžik; Viljemka Bučević-Popović; Marijan Šitum; Crystal J Jaing; Marina Degoricija; Kevin S McLoughlin; Said I Ismail; Volga Punda-Polić; Janoš Terzić
Journal:  Tumour Biol       Date:  2014-01

7.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

8.  LL-37 disrupts the Kaposi's sarcoma-associated herpesvirus envelope and inhibits infection in oral epithelial cells.

Authors:  David C Brice; Zsolt Toth; Gill Diamond
Journal:  Antiviral Res       Date:  2018-08-02       Impact factor: 5.970

9.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 10.  Kaposi sarcoma.

Authors:  Ethel Cesarman; Blossom Damania; Susan E Krown; Jeffrey Martin; Mark Bower; Denise Whitby
Journal:  Nat Rev Dis Primers       Date:  2019-01-31       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.